- Home
- GROY vs MLTX Comparison
GROY vs MLTX Comparison
Compare GROY & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GROY | MLTX |
|---|---|---|
| Founded | 2020 | 2021 |
| Country | Canada | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GROY | MLTX |
|---|---|---|
| Price | $3.23 | $16.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 12 |
| Target Price | $5.90 | ★ $30.58 |
| AVG Volume (30 Days) | ★ 2.6M | 874.2K |
| Earning Date | 03-18-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $147.12 | N/A |
| Revenue Next Year | $51.16 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.23 | $5.95 |
| 52 Week High | $5.45 | $62.75 |
Technical Indicators
Market Signals| Indicator | GROY | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 26.94 | 48.25 |
| Support Level | $2.89 | $14.84 |
| Resistance Level | $3.26 | $19.03 |
| Average True Range (ATR) | 0.21 | 0.73 |
| MACD | -0.12 | -0.22 |
| Stochastic Oscillator | 11.84 | 29.60 |
Price Performance
Historical ComparisonAbout GROY Gold Royalty Corp.
Gold Royalty Corp is a precious metals-focused royalty and mineral streaming company. The company offers creative financing solutions to the metals and mining industry. The company's mission is to acquire royalties, streams and similar interests at varying stages of the mine life cycle to build a balanced portfolio offering near, medium and longer-term attractive returns for investors. It has its business as a single operating segment, being the investment in royalty and mineral stream interests. The company derives maximum revenue from Canada.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.